CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) was the target of a large increase in short interest in the month of December. As of December 30th, there was short interest totalling 3,710,000 shares, an increase of 7.8% from the December 15th total of 3,440,000 shares. Based on an average daily trading volume, of 602,000 shares, the days-to-cover ratio is currently 6.2 days.
Institutional Investors Weigh In On CymaBay Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Raymond James & Associates grew its holdings in shares of CymaBay Therapeutics by 26.3% in the first quarter. Raymond James & Associates now owns 97,604 shares of the biopharmaceutical company’s stock valued at $304,000 after acquiring an additional 20,337 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of CymaBay Therapeutics by 8.6% during the 1st quarter. Bank of New York Mellon Corp now owns 276,766 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 21,961 shares during the last quarter. MetLife Investment Management LLC bought a new stake in shares of CymaBay Therapeutics during the 1st quarter worth $163,000. BlackRock Inc. boosted its holdings in shares of CymaBay Therapeutics by 2.7% in the 1st quarter. BlackRock Inc. now owns 5,466,209 shares of the biopharmaceutical company’s stock worth $16,998,000 after buying an additional 142,081 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in CymaBay Therapeutics by 18.4% during the first quarter. Dimensional Fund Advisors LP now owns 940,806 shares of the biopharmaceutical company’s stock valued at $2,926,000 after buying an additional 145,965 shares during the period. 73.54% of the stock is owned by institutional investors.
CymaBay Therapeutics Stock Up 3.9 %
Shares of NASDAQ:CBAY opened at $6.94 on Monday. The business’s 50 day moving average is $4.82 and its 200 day moving average is $3.99. CymaBay Therapeutics has a 12-month low of $1.67 and a 12-month high of $7.15. The stock has a market cap of $587.67 million, a price-to-earnings ratio of -5.55 and a beta of 0.19. The company has a quick ratio of 12.20, a current ratio of 12.20 and a debt-to-equity ratio of 1.43.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on CBAY shares. Oppenheimer reduced their price objective on CymaBay Therapeutics to $10.00 in a research note on Thursday, November 17th. StockNews.com assumed coverage on shares of CymaBay Therapeutics in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, Raymond James upped their price objective on shares of CymaBay Therapeutics from $14.00 to $17.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 17th. One investment analyst has rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $11.25.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
- Get a free copy of the StockNews.com research report on CymaBay Therapeutics (CBAY)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.